North America Botulinum Toxin Market Forecast to 2031
North America Botulinum Toxin Market Forecast to 2031 – Regional Analysis – by Product (Botulinum Toxin A and Botulinum Toxin B), Application (Medical and Aesthetic), and End User (Specialty & Dermatology Clinics, Hospitals & Clinics, and Others)
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Expanding Therapeutic Applications Fuel North America Botulinum Toxin Market
The botulinum toxins type A and B block vesicular acetylcholine released at neuromuscular and neurosecretory junctions, thereby delivering powerful therapeutic outcomes for treating patients requiring neurorehabilitation intervention. As per clinical reports, botulinum toxins have been proven to have therapeutic effects against headache, salivate, and hyperhidrosis, among others. Botulinum treatment can be adopted as an alternative to surgery. It appears to be a promising alternative to sphincterotomy in patients with chronic anal fissures. Patients suffering from a few autonomic disorders such as ptyalism or gustatory sweating, and hypersecretion of glands (a condition that often occurs after patients undergo surgeries involving parotid glands) respond well to botulinum toxins. Despite numerous advancements in the field of assisted reproductive technology, a significant number of patients still suffer from repeated implantation failure. Adequate endometrial growth plays a crucial role in embryo implantation and pregnancy continuation in an assisted reproductive procedure. For several years, botulinum toxins have been widely used in plastic and aesthetic surgeries; it has been revealed that botulinum toxins have a positive influence on the re-epithelialization of human keratinocytes and the angiogenesis of endothelial cells. Clinical results reveal that botulinum toxin administration facilitates the recovery of damaged structure and impaired function of the thin endometrium by increasing cellular proliferation and vessel formation, reducing collagen-accumulated lesions, and ultimately contributing to successful embryo implantation. Thus, the expanding therapeutic applications of botulinum toxins are likely to bring new botulinum toxins market trends in the coming years.
North America Botulinum Toxin Market Overview
The North America botulinum toxin market is segmented into the US, Canada, and Mexico. The market growth in North America can be mainly associated with the economically stable population and increasing numbers of nonsurgical or minimally invasive cosmetic procedures performed in the abovementioned countries. Reduction of facial wrinkles with botulinum toxin injections is the most performed cosmetic procedure in the US. It is one of the most common entry-level procedures for clinicians willing to incorporate aesthetic treatments into their practice. According to the International Society of Aesthetic Plastic Surgery (ISAPS), nearly 2.5 million botulinum toxin procedures were performed in the US in 2021. The treatment of frown lines and crow’s feet approved by the US Food and Drug Administration- for cosmetic indications and horizontal forehead wrinkles provide predictable results, have few side effects, and high patient satisfaction. BOTOX Cosmetic/Vistabel by Allergan, Dysport/Azzalure by Galderma and Ipsen, Xeomin/Bocouture by Merz, and Jeuveau by Evolus (manufactured only by Daewoong for the US) are among the commercially available botulinum toxin products in the country. The US FDA has approved BOTOX Cosmetic for people from the age range of 18–65. According to the American Society for Aesthetic Plastic Surgery, botox injection is the fastest-growing procedure in the cosmetic industry. In August 2023, Daxxify (daxibotulinumtoxinA-lanm) was approved by the FDA as the first therapeutic indication to treat adult cervical dystonia. Cervical dystonia is characterized by uncontrollably occurring spasms or contractions in neck muscles, causing unusual movements, awkward posture, and head and neck pain. This condition affects approximately 60,000 Americans. The injection of botulinum toxin facilitates the relaxation of affected muscles in cervical dystonia patients, thereby reducing stiffness and spasms. However, the effect of the treatment slowly wears off, and thus, patients need frequent retreatments. Earlier, in July 2021, the FDA approved the label expansion of BOTOX Cosmetic of Allergan, an AbbVie company. Allergan has expanded BOTOX’s applications to treat 8 new muscle conditions related to upper limb spasticity in adults.
North America Botulinum Toxin Market Revenue and Forecast to 2031 (US$ Million)
North America Botulinum Toxin Market Segmentation
The North America botulinum toxin market is categorized into product, application, end user, and country.
Based on product, the North America botulinum toxin market is bifurcated into botulinum toxin A and botulinum toxin B. The botulinum toxin A segment held the larger share of North America botulinum toxin market share in 2023.
In terms of application, the North America botulinum toxin market is bifurcated into medical and aesthetic. The medical segment held the larger share of North America botulinum toxin market in 2023. Furthermore, the medical segment is subcategorized into chronic migraine, muscle spasm, over reactive bladder, hyperhidrosis, and others. Additionally, the aesthetic segment is subcategorized into frown lines/ glabellar, forehead lines, crow’s feet, square jaw/ masseter, and others.
By end user, the North America botulinum toxin market is divided into specialty & dermatology clinics, hospitals & clinics, and others. The specialty and dermatology clinics segment held the largest share of North America botulinum toxin market in 2023.
Based on country, the North America botulinum toxin market is segmented into the US, Canada, and Mexico. The US dominated the North America botulinum toxin market share in 2023.
Merz Pharma GmbH & Co KGaA, AbbVie Inc, Ipsen SA, Evolus Inc, Aquavit, Revance Therapeutics Inc, Medytox Inc, Galderma SA, Hugel Inc, and Lanzhou Institute of Biological Products Co Ltd are some of the leading companies operating in the North America botulinum toxin market.
Summary Info
Industry: | |
---|---|
Pricing options: | |
Geographical coverage: | |
Year of Publication: |
According to The Research Team’ research, the North America botulinum toxin market was valued at US$ 4,801.29 million in 2023 and is expected to reach US$ 12,072.60 million by 2031, registering a CAGR of 12.2% from 2023 to 2031. Rising popularity of noninvasive aesthetics procedures and increasing use of botulinum toxin for enhancing facial aesthetics are among the critical factors attributed to drive the North America botulinum toxin market growth.
Noninvasive procedures include facial rejuvenation, injections which includes botulinum toxin, calcium hydroxyapatite, and hyaluronic acid, and others. These procedures help reduce cellulite, wrinkles, facial lines, and unwanted fat with minimal side effects. The concept of natural rejuvenation is based on a comprehensive, multilayered, three-dimensional approach that combines multiple techniques and active ingredients in procedures such as volume enlargement, skin relaxation, reshaping, volume repositioning, skin tightening, and surface renewal, depending on specific needs of patients. The most often used non-surgical face procedures are chemical peels, laser skin resurfacing, soft tissue fillers, and Botox. Unlike surgical procedures that are associated with greater risks, minimally invasive procedures benefit patients through faster recovery, lesser scarring, limited stress, and better patient satisfaction. Moreover, changing consumer views about wellness, beauty, and good aging results in a better understanding and acceptance of aesthetics worldwide. According to the International Society of Aesthetic Plastic Surgery (ISAPS), the number of nonsurgical procedures increased by 19.9% in 2021 compared to 2020. The total number of nonsurgical procedures was 17.5 million in 2021. Thus, an upsurge in the adoption of noninvasive aesthetic procedures is driving the growth of the botulinum toxin market.
On the contrary, side effects of botulinum toxin hamper the growth of North America botulinum toxin market.
Based on product, the North America botulinum toxin market is bifurcated into botulinum toxin A and botulinum toxin B. The botulinum toxin A segment held 98.3% share of North America botulinum toxin market share in 2023, amassing US$ 4,721.11 million. It is projected to garner US$ 11,934.23 million by 2031 to register 12.3% CAGR during 2023–2031.
In terms of application, the North America botulinum toxin market is bifurcated into medical and aesthetic. The medical segment held 56.6% share of North America botulinum toxin market in 2023, amassing US$ 2,716.77 million. It is anticipated to garner US$ 7,198.56 million by 2031 to expand at 13.0% CAGR during 2023–2031. Furthermore, the medical segment is subcategorized into chronic migraine, muscle spasm, over reactive bladder, hyperhidrosis, and others. Additionally, the aesthetic segment is subcategorized into frown lines/ glabellar, forehead lines, crow’s feet, square jaw/ masseter, and others.
By end user, the North America botulinum toxin market is divided into specialty & dermatology clinics, hospitals & clinics, and others. The specialty and dermatology clinics segment held 49.7% share of North America botulinum toxin market in 2023, amassing US$ 2,388.11 million. It is projected to garner US$ 6,368.10 million by 2031 to expand at 13.0% CAGR from 2023 to 2031.
Based on country, the North America botulinum toxin market is categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 95.3% share of North America botulinum toxin market in 2023. It was assessed at US$ 4,574.57 million in 2023 and is likely to hit US$ 11,366.36 million by 2031, registering a CAGR of 12.0% during 2023–2031.
Key players operating in the North America botulinum toxin market are Merz Pharma GmbH & Co KGaA, AbbVie Inc, Ipsen SA, Evolus Inc, Aquavit, Revance Therapeutics Inc, Medytox Inc, Galderma SA, Hugel Inc, and Lanzhou Institute of Biological Products Co Ltd, among others.
In February-2022, Merz Therapeutics is expanding its strategic partnership with Vensica Therapeutics as the Merz Group invests up to US$3 million in the Israeli start-up. This investment follows the strategic license and collaboration agreement signed in 2021 to utilize Merz’s botulinum neurotoxin A (XEOMIN) for the innovative ultrasound-assisted delivery catheter of Vensica. Merz is thus executing its contractually agreed option to participate in Vensica’s Series C financing round and invest further in the start-up.
In August-2021, Merz Therapeutics and the Israeli start-up Vensica Therapeutics Ltd., a urology company, announced that they have entered into a strategic license and collaboration agreement to deliver botulinum neurotoxin A (XEOMIN)to the bladder wall by using Vensica’s innovative ultrasound-assisted delivery catheter. By this, Merz Therapeutics becomes the exclusive toxin supplier of any needleless application for urological indications, such as overactive bladder, neurogenic bladder, interstitial cystitis, and other urology indications.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the North America botulinum toxin market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America botulinum toxin market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
1. Introduction
1.1 The Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Botulinum Toxin Market – Key Market Dynamics
4.1 Market Drivers
4.1.1 Rising Popularity of Noninvasive Aesthetics Procedures
4.1.2 Increasing Use of Botulinum Toxin for Enhancing Facial Aesthetics
4.2 Market Restraints
4.2.1 Side Effects of Botulinum Toxin
4.3 Market Opportunities
4.3.1 Rising Adoption of Aesthetic Procedure in Emerging Economies
4.4 Future Trends
4.4.1 Expanding Therapeutic Applications
4.5 Impact of Drivers and Restraints:
5. Botulinum Toxin Market – North America Analysis
5.1 Overview
5.2 Botulinum Toxin Market Revenue (US$ Million), 2021–2031
6. North America Botulinum Toxin Market Analysis – by Product
6.1 Overview
6.2 Botulinum Toxin A
6.2.1 Overview
6.2.2 Botulinum Toxin A: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
6.3 Botulinum Toxin B
6.3.1 Overview
6.3.2 Botulinum Toxin B: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
7. North America Botulinum Toxin Market Analysis – by Application
7.1 Overview
7.2 Medical
7.2.1 Overview
7.2.2 Medical: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
7.2.2.1 North America Botulinum Toxin Market Breakdown, by Medical
7.3 Aesthetic
7.3.1 Overview
7.3.2 Aesthetic: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
7.3.2.1 North America Botulinum Toxin Market Breakdown, by Aesthetic
8. North America Botulinum Toxin Market Analysis – by End User
8.1 Overview
8.2 Specialty and Dermatology Clinics
8.2.1 Overview
8.2.2 Specialty and Dermatology Clinics: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
8.3 Hospitals and Clinics
8.3.1 Overview
8.3.2 Hospitals and Clinics: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9. North America Botulinum Toxin Market – Country Analysis
9.1 North America: Botulinum Toxin Market
9.1.1 North America: Botulinum Toxin Market – Revenue and Forecast Analysis – by Country
9.1.1.1 United States: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.1.1 Overview
9.1.1.1.2 United States: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.1.3 United States: Botulinum Toxin Market Breakdown, by Product
9.1.1.1.4 United States: Botulinum Toxin Market Breakdown, by Application
9.1.1.1.4.1 United States: Botulinum Toxin Market Breakdown, by Medical
9.1.1.1.4.2 United States: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.1.5 United States: Botulinum Toxin Market Breakdown, by End User
9.1.1.2 Canada: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.2.1 Overview
9.1.1.2.2 Canada: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.2.3 Canada: Botulinum Toxin Market Breakdown, by Product
9.1.1.2.4 Canada: Botulinum Toxin Market Breakdown, by Application
9.1.1.2.4.1 Canada: Botulinum Toxin Market Breakdown, by Medical
9.1.1.2.4.2 Canada: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.2.5 Canada: Botulinum Toxin Market Breakdown, by End User
9.1.1.3 Mexico: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.3.1 Overview
9.1.1.3.2 Mexico: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.3.3 Mexico: Botulinum Toxin Market Breakdown, by Product
9.1.1.3.4 Mexico: Botulinum Toxin Market Breakdown, by Application
9.1.1.3.4.1 Mexico: Botulinum Toxin Market Breakdown, by Medical
9.1.1.3.4.2 Mexico: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.3.5 Mexico: Botulinum Toxin Market Breakdown, by End User
10. Company Profiles
10.1 Merz Pharma GmbH & Co KGaA
10.1.1 Key Facts
10.1.2 Business Description
10.1.3 Products and Services
10.1.4 Financial Overview
10.1.5 SWOT Analysis
10.1.6 Key Developments
10.2 AbbVie Inc
10.2.1 Key Facts
10.2.2 Business Description
10.2.3 Products and Services
10.2.4 Financial Overview
10.2.5 SWOT Analysis
10.2.6 Key Developments
10.3 Ipsen SA
10.3.1 Key Facts
10.3.2 Business Description
10.3.3 Products and Services
10.3.4 Financial Overview
10.3.5 SWOT Analysis
10.3.6 Key Developments
10.4 Evolus Inc
10.4.1 Key Facts
10.4.2 Business Description
10.4.3 Products and Services
10.4.4 Financial Overview
10.4.5 SWOT Analysis
10.4.6 Key Developments
10.5 Aquavit
10.5.1 Key Facts
10.5.2 Business Description
10.5.3 Products and Services
10.5.4 Financial Overview
10.5.5 SWOT Analysis
10.5.6 Key Developments
10.6 Revance Therapeutics Inc
10.6.1 Key Facts
10.6.2 Business Description
10.6.3 Products and Services
10.6.4 Financial Overview
10.6.5 SWOT Analysis
10.6.6 Key Developments
10.7 Medytox Inc
10.7.1 Key Facts
10.7.2 Business Description
10.7.3 Products and Services
10.7.4 Financial Overview
10.7.5 SWOT Analysis
10.7.6 Key Developments
10.8 Galderma SA
10.8.1 Key Facts
10.8.2 Business Description
10.8.3 Products and Services
10.8.4 Financial Overview
10.8.5 SWOT Analysis
10.8.6 Key Developments
10.9 Hugel Inc
10.9.1 Key Facts
10.9.2 Business Description
10.9.3 Products and Services
10.9.4 Financial Overview
10.9.5 SWOT Analysis
10.9.6 Key Developments
10.10 Lanzhou Institute of Biological Products Co Ltd
10.10.1 Key Facts
10.10.2 Business Description
10.10.3 Products and Services
10.10.4 Financial Overview
10.10.5 SWOT Analysis
10.10.6 Key Developments
11. Appendix
11.1 About The Research Team
Table 1. Botulinum Toxin Market Segmentation
Table 2. North America Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Medical
Table 3. North America Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Aesthetic
Table 4. United States: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Product
Table 5. United States: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Application
Table 6. United States: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Medical
Table 7. United States: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Aesthetic
Table 8. United States: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 9. Canada: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Product
Table 10. Canada: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Application
Table 11. Canada: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Medical
Table 12. Canada: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Aesthetic
Table 13. Canada: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 14. Mexico: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Product
Table 15. Mexico: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Application
Table 16. Mexico: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Medical
Table 17. Mexico: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Aesthetic
Table 18. Mexico: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 19. Glossary of Terms
Figure 1. Botulinum Toxin Market Segmentation, by Country
Figure 2. Botulinum Toxin Market – Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Botulinum Toxin Market Revenue (US$ Million), 2021–2031
Figure 5. Botulinum Toxin Market Share (%) – by Product (2023 and 2031)
Figure 6. Botulinum Toxin A: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 7. Botulinum Toxin B: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 8. Botulinum Toxin Market Share (%) – by Application (2023 and 2031)
Figure 9. Medical: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 10. Aesthetic: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 11. Botulinum Toxin Market Share (%) – by End User (2023 and 2031)
Figure 12. Specialty and Dermatology Clinics: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 13. Hospitals and Clinics: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 14. Others: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 15. North America: Botulinum Toxin Market, by Key Country – Revenue (2023) (US$ Million)
Figure 16. North America: Botulinum Toxin Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 17. United States: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 18. Canada: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 19. Mexico: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
The List of Companies – North America Botulinum Toxin Market
o Merz Pharma GmbH & Co KGaA
o AbbVie Inc
o Ipsen SA
o Evolus Inc
o Aquavit
o Revance Therapeutics Inc
o Medytox Inc
o Galderma SA
o Hugel Inc
o Lanzhou Institute of Biological Products Co Ltd
You must be logged in to post a review.
Reviews
There are no reviews yet.